久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Basic Info

  • Grade: Pharmaceutical Grade

    Factory Location: EU-Poland

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: yes

    Payment Terms: L/C

    Risdiplam

    Status Pipeline
    Development phase Initial stage
    Therapeutic cat. Musculo-skeletal
    CAS No. 1825352-65-5
    OEB No.

    4

    Drug description

    Risdiplam is an oral mRNA splicing modifier used in the treatment of spinal muscular atrophy (SMA).

     

    Disclaimer: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

     

Send your message to this supplier
  • From:
  • To:
    Polpharma
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service